Multicenter Studies on Asbestos

PubMed, the National Library of Medicine's index of medical journals, labels every article with its publication type. 306 studies in our library are labeled as studies carried out at more than one hospital or research center. The labels are NLM's, not ours. Each entry links to the study on PubMed and to its journal's page in our library, where you can read the abstract.

2020s

• Comprehensive characterisation of individuals with fibrotic interstitial lung disease: baseline insights from the INJUSTIS study. F. Khan, I. Stewart, L. Howard, et al. BMJ Open Respiratory Research 2026;13(1). PubMed · Publisher · Free full text
• Isolated Peripheral Nervous System Presentation in Ma/Ma2-Associated Autoimmunity. A. Vilaseca, M. Villagrán-García, A. Farina, et al. Neurology® Neuroimmunology & Neuroinflammation 2026;13(5):e200623. PubMed · Publisher · Free full text
• Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study. O. Aydin, Z.S. Isleyen, M. Erciyestepe, et al. Scientific Reports 2026;16(1). PubMed · Publisher · Free full text
• Understanding pain in malignant mesothelioma: a prospective, longitudinal cohort study. C.R. Mayland, M. Collinson, S.H. Ahmedzai, et al. BMC Palliative Care 2026;25(1). PubMed · Publisher · Free full text
• A Multi-Center Real-World Study of Clinicopathologic Characteristics and Efficacy of the Malignant Mesothelioma in Chinese Population. C. Sun, X. Yang, L. Chen, et al. Thoracic Cancer 2025;16(3):e15533. PubMed · Publisher · Free full text
• Characteristics of Long-term Survivors With Malignant Pleural Mesothelioma. I. Opitz, O. Lauk, R. Werner, et al. The Annals of Thoracic Surgery 2025;120(1):108-116. PubMed · Publisher
• Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma. L. Möhrmann, M. Werner, M. Oleś, et al. ESMO Open 2025;10(4):104532. PubMed · Publisher · Free full text
• Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA. L.H. Douma, M.M. Hofman, F. Zwierenga, et al. ESMO Open 2025;10(2):104123. PubMed · Publisher · Free full text
• KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. T. Kijima, T. Kato, Y. Goto, et al. Cancer Science 2025;116(8):2208-2217. PubMed · Publisher · Free full text
• Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. S. Thunold, E. Hernes, S. Farooqi, et al. European Journal of Nuclear Medicine and Molecular Imaging 2025;52(2):693-707. Randomized trial PubMed · Publisher · Free full text
• Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses. J.E. Reuss, P.K. Lee, R.J. Mehran, et al. Nature Medicine 2025;31(12):4097-4108. PubMed · Publisher · Free full text
• Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. J. Fang, O. Jiang, W. Li, et al. Drug Design, Development and Therapy 2025;19:10423-10435. PubMed · Publisher · Free full text
• Quality of life in patients with PICC diagnosed with mesothelioma: Results of a multicenter epidemiological survey (LifePICC). T. Bolgeo, R. Di Matteo, S. Crivellari, et al. The Journal of Vascular Access 2025;26(1):217-227. PubMed · Publisher
• Sex-Differences in Alpha-1 Antitrypsin Deficiency: Data From the EARCO Registry. H. Ersöz, M. Torres-Durán, A.M. Turner, et al. Archivos de Bronconeumología 2025;61(1):22-30. In English, Spanish. PubMed · Publisher
• The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis. N. Sever, S. Yıldırım, A.F. Gurbuz, et al. Medicina 2025;61(1). PubMed · Publisher · Free full text
• A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. M. Zhang, A. Bzura, E.Y. Baitei, et al. Nature Communications 2024;15(1):7187. PubMed · Publisher · Free full text
• A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. C.C. Lin, E. Garralda, P. Schöffski, et al. Oncoimmunology 2024;13(1):2290787. PubMed · Publisher · Free full text
• A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205. J. Raskin, V. Surmont, A.P.W.M. Maat, et al. The European Respiratory Journal 2024;63(6). Randomized trial PubMed · Publisher · Free full text
• Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study. S. Yaşar, F. Yılmaz, G. Utkan, et al. Annals of Surgical Oncology 2024;31(9):6228-6236. PubMed · Publisher · Free full text
• ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study. S. Yaşar. Annals of Surgical Oncology 2024;31(9):6276-6277. PubMed · Publisher · Free full text
• Building an Efficient Peritoneal Surface Malignancies Program Despite the Lower-Middle-Income Barriers: Ukraine Experience. V. Kopetskyi, M. Antoniv, R. Yarema, et al. JCO Global Oncology 2024;10:e2300432. PubMed · Publisher · Free full text
• Development of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma. A.E.J. Gibson, W. Ahmed, L. Longworth, et al. The Patient 2024;17(5):551-563. PubMed · Publisher
• Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. E. Lim, D. Waller, K. Lau, et al. The Lancet. Respiratory Medicine 2024;12(6):457-466. Randomized trial PubMed · Publisher · Free full text
• Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. A.S. Mansfield, J. Vivien Yin, P. Bradbury, et al. Lung Cancer 2024;195:107928. Randomized trial PubMed · Publisher · Free full text
• Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study. N. Fujimoto, A. Akamatsu, C. Honda, et al. Japanese Journal of Clinical Oncology 2024;54(12):1321-1328. PubMed · Publisher · Free full text
• Artificial intelligence-based diagnosis of asbestosis: analysis of a database with applicants for asbestosis state aid. K.B.W. Groot Lipman, C.J. de Gooijer, T.N. Boellaard, et al. European Radiology 2023;33(5):3557-3565. PubMed · Publisher · Free full text
• Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma. F.X. Danlos, M. Texier, B. Job, et al. Cancer Discovery 2023;13(4):858-879. PubMed · Publisher · Free full text
• Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma. T. Kutuk, J.M. Walker, M.T. Ballo, et al. Current Oncology 2023;30(6):5195-5200. PubMed · Publisher · Free full text
• Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. N. de Rouw, R.J. Boosman, J.A. Burgers, et al. Cancer Chemotherapy and Pharmacology 2023;91(1):33-42. Randomized trial PubMed · Publisher · Free full text
• The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. T. Kurosaki, K. Chamoto, S. Suzuki, et al. Frontiers in Immunology 2023;14:1325462. PubMed · Publisher · Free full text
• Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. W. Sun, W. Wu, Q. Wang, et al. Journal of Translational Medicine 2022;20(1):114. PubMed · Publisher · Free full text
• Deep Learning for the Automatic Quantification of Pleural Plaques in Asbestos-Exposed Subjects. I. Benlala, B.D. De Senneville, G. Dournes, et al. International Journal of Environmental Research and Public Health 2022;19(3). PubMed · Publisher · Free full text
• Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. L. Mannarino, L. Paracchini, F. Pezzuto, et al. International Journal of Molecular Sciences 2022;23(10). PubMed · Publisher · Free full text
• Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. S. Canova, G.L. Ceresoli, F. Grosso, et al. ESMO Open 2022;7(6):100644. PubMed · Publisher · Free full text
• Frequency of Asbestos Exposure and Histological Subtype of Ovarian Carcinoma. P. Vidican, O. Perol, J. Fevotte, et al. International Journal of Environmental Research and Public Health 2022;19(9). PubMed · Publisher · Free full text
• Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region. H. Uramoto, T. Takiguchi, T. Koizumi, et al. Journal of Cancer Research and Clinical Oncology 2022;148(5):1153-1158. PubMed · Publisher · Free full text
• Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. O.E. Rahma, K. Tyan, A. Giobbie-Hurder, et al. Journal for Immunotherapy of Cancer 2022;10(3). PubMed · Publisher · Free full text
• Pleural mesothelioma risk by industry and occupation: results from the Multicentre Italian Study on the Etiology of Mesothelioma (MISEM). E. Migliore, D. Consonni, S. Peters, et al. Environmental Health 2022;21(1):60. PubMed · Publisher · Free full text
• Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. J.R. Miedema, C.C. Moor, M. Veltkamp, et al. Respiratory Research 2022;23(1):139. PubMed · Publisher · Free full text
• Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. T. Nakano, K. Kuribayashi, M. Kondo, et al. Asia-Pacific Journal of Clinical Oncology 2021;17(3):264-272. PubMed · Publisher · Free full text
• Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study. N. Benzerdjeb, P. Dartigues, V. Kepenekian, et al. Virchows Archiv 2021;479(5):927-936. PubMed · Publisher
• Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. R.Y. Kim, Y. Li, M.E. Marmarelis, et al. Lung Cancer 2021;159:107-110. PubMed · Publisher · Free full text
• CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. R.E. Sanborn, O. Hamid, E.G. de Vries, et al. Journal for Immunotherapy of Cancer 2021;9(7). PubMed · Publisher · Free full text
• Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. P.M. Forde, V. Anagnostou, Z. Sun, et al. Nature Medicine 2021;27(11):1910-1920. PubMed · Publisher · Free full text
• Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study. S. Yilmaz, N.Y. Demirci, S. Metintas, et al. Journal of Occupational and Environmental Medicine 2021;63(3):238-243. PubMed · Publisher
• Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. T.A. Yap, K. Nakagawa, N. Fujimoto, et al. The Lancet. Respiratory Medicine 2021;9(6):613-621. PubMed · Publisher
• Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. C. Pinto, P.A. Zucali, M. Pagano, et al. The Lancet. Oncology 2021;22(10):1438-1447. Randomized trial PubMed · Publisher
• JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. Y. Miyamoto, T. Kozuki, K. Aoe, et al. Journal for Immunotherapy of Cancer 2021;9(10). PubMed · Publisher · Free full text
• Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. K. Makita, Y. Hamamoto, H. Kanzaki, et al. Radiation Oncology 2021;16(1):225. PubMed · Publisher · Free full text
• Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. D.B. Chapel, J.J. Schulte, G. Absenger, et al. Modern Pathology 2021;34(2):380-395. PubMed · Publisher
• NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. V.D. Haakensen, A.K. Nowak, E.B. Ellingsen, et al. Journal of Translational Medicine 2021;19(1):232. Randomized trial PubMed · Publisher · Free full text
• Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. D.A. Fennell, S. Ewings, C. Ottensmeier, et al. The Lancet. Oncology 2021;22(11):1530-1540. Randomized trial PubMed · Publisher · Free full text
• Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. M.G. Zauderer, E.W. Alley, J. Bendell, et al. Investigational New Drugs 2021;39(4):1081-1088. PubMed · Publisher · Free full text
• Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J.J. Luke, F. Barlesi, K. Chung, et al. Journal for Immunotherapy of Cancer 2021;9(2). PubMed · Publisher · Free full text
• Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. J. Behr, A. Prasse, M. Kreuter, et al. The Lancet. Respiratory Medicine 2021;9(5):476-486. Randomized trial PubMed · Publisher
• Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. D.A. Fennell, A. King, S. Mohammed, et al. The Lancet. Respiratory Medicine 2021;9(6):593-600. Randomized trial PubMed · Publisher
• Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. S. Tsim, L. Alexander, C. Kelly, et al. Journal of Thoracic Oncology 2021;16(10):1705-1717. PubMed · Publisher · Free full text
• Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. C.J. de Gooijer, V. van der Noort, J.A. Stigt, et al. The Lancet. Respiratory Medicine 2021;9(6):585-592. Randomized trial PubMed · Publisher
• Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study. S.N. Hoon, I. Lawrie, C. Qi, et al. Journal of Palliative Care 2021;36(2):113-120. Randomized trial PubMed · Publisher
• Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. D. Cortinovis, F. Grosso, L. Carlucci, et al. Clinical Lung Cancer 2021;22(4):361-370.e3. PubMed · Publisher
• A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. S. Popat, A. Curioni-Fontecedro, U. Dafni, et al. Annals of Oncology 2020;31(12):1734-1745. PubMed · Publisher
• A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. E.M.J. van Brummelen, E. Levchenko, M. Dómine, et al. Investigational New Drugs 2020;38(2):457-467. PubMed · Publisher · Free full text
• Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. T. Ikeda, S. Takemoto, H. Senju, et al. Thoracic Cancer 2020;11(7):1972-1978. PubMed · Publisher · Free full text
• Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. A. Marabelle, M. Fakih, J. Lopez, et al. The Lancet. Oncology 2020;21(10):1353-1365. PubMed · Publisher
• Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. A. Brandl, S. Westbrook, S. Nunn, et al. BJS Open 2020;4(2):260-267. PubMed · Publisher · Free full text
• Combined effects of occupational exposure to hazardous operations and lifestyle-related factors on cancer incidence. K. Fukai, N. Kojimahara, K. Hoshi, et al. Cancer Science 2020;111(12):4581-4593. PubMed · Publisher · Free full text
• Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. A. Bilecz, P. Stockhammer, D. Theegarten, et al. Histopathology 2020;77(1):55-66. PubMed · Publisher
• Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. F. Galateau Salle, N. Le Stang, F. Tirode, et al. Journal of Thoracic Oncology 2020;15(6):1037-1053. PubMed · Publisher · Free full text
• COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. M.C. Garassino, J.G. Whisenant, L.C. Huang, et al. The Lancet. Oncology 2020;21(7):914-922. PubMed · Publisher · Free full text
• Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. A.K. Nowak, W.J. Lesterhuis, P.S. Kok, et al. The Lancet. Oncology 2020;21(9):1213-1223. PubMed · Publisher
• First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. R. Hassan, G.R. Blumenschein, K.N. Moore, et al. Journal of Clinical Oncology 2020;38(16):1824-1835. PubMed · Publisher · Free full text
• Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. S. Dacic, N. Le Stang, A. Husain, et al. Modern Pathology 2020;33(2):255-262. PubMed · Publisher
• MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. D.B. Chapel, J.J. Schulte, K. Berg, et al. Modern Pathology 2020;33(2):245-254. PubMed · Publisher
• Number of mesothelial cells as a measure of adequacy criteria for pleural effusions: A multi-institutional study. E.F. Rodriguez, P.C. Morris, V. Calsavara, et al. Cytopathology 2020;31(3):223-227. PubMed · Publisher
• Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. L.H. Boal, J. Glod, M. Spencer, et al. Clinical Cancer Research 2020;26(23):6112-6121. PubMed · Publisher · Free full text
• Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. B. Geoerger, H.J. Kang, M. Yalon-Oren, et al. The Lancet. Oncology 2020;21(1):121-133. PubMed · Publisher
• Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. M.Y. Zaidi, R.M. Lee, A.C. Gamboa, et al. Annals of Surgical Oncology 2020;27(1):156-164. PubMed · Publisher · Free full text
• Short-term integrated rehabilitation for people with newly diagnosed thoracic cancer: a multi-centre randomized controlled feasibility trial. J. Bayly, L. Fettes, E. Douglas, et al. Clinical Rehabilitation 2020;34(2):205-219. Randomized trial PubMed · Publisher
• Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis. F. Lococo, F. Torricelli, L. Lang-Lazdunski, et al. The Journal of Thoracic and Cardiovascular Surgery 2020;159(4):1584-1593.e2. PubMed · Publisher
• Tribal Odisha Eye Disease Study Report # 6. Opportunistic screening of vitamin A deficiency through School Sight Program in tribal Odisha (India). L. Panda, S. Nayak, T. Das. Indian Journal of Ophthalmology 2020;68(2):351-355. PubMed · Publisher · Free full text

2010s

• Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. S. Tsim, S. Paterson, D. Cartwright, et al. Lung Cancer 2019;133:123-129. PubMed · Publisher

• Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. R. Hassan, E. Alley, H. Kindler, et al. Clinical Cancer Research 2019;25(19):5787-5798. PubMed · Publisher · Free full text

• Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma. L. Wijmans, P. Baas, T.E. Sieburgh, et al. Chest 2019;156(4):754-763. PubMed · Publisher

• Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy. F. Luberto, D. Ferrante, S. Silvestri, et al. Environmental Health 2019;18(1):71. PubMed · Publisher · Free full text

• Endoscopic Ultrasound with Bronchoscope-Guided Fine Needle Aspiration for the Diagnosis of Paraesophageally Located Lung Lesions. I. Skovgaard Christiansen, J.C. Kuijvenhoven, U. Bodtger, et al. Respiration; International Review of Thoracic Diseases 2019;97(4):277-283. Case report PubMed · Publisher · Free full text

• Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy. M. Trovo, D. Franceschini, C. Furlan, et al. La Radiologia Medica 2019;124(9):854-859. PubMed · Publisher

• I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. S. Ekman, F. Griesinger, P. Baas, et al. Future Oncology 2019;15(14):1551-1563. PubMed · Publisher

• Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?. S. Kim, D.A. Bull, L. Garland, et al. The Annals of Thoracic Surgery 2019;107(1):194-201. PubMed · Publisher

• Multicentre, population-based, case-control study of particulates, combustion products and amyotrophic lateral sclerosis risk. A.E. Visser, F. D'Ovidio, S. Peters, et al. Journal of Neurology, Neurosurgery, and Psychiatry 2019;90(8):854-860. PubMed · Publisher

• Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. A. Scherpereel, J. Mazieres, L. Greillier, et al. The Lancet. Oncology 2019;20(2):239-253. Randomized trial PubMed · Publisher

• Occupational exposure to wood dust and risk of lung cancer: the ICARE study. M. Matrat, L. Radoï, J. Févotte, et al. Occupational and Environmental Medicine 2019;76(12):901-907. PubMed · Publisher

• Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study. O. Sgarbura, M. Hübner, M. Alyami, et al. European Journal of Surgical Oncology 2019;45(12):2386-2391. PubMed · Publisher

• Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. M.W. Marcus, S.W. Duffy, A. Devaraj, et al. Thorax 2019;74(8):761-767. Randomized trial PubMed · Publisher

• Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma. R. White, E. Pulford, D.J. Elliot, et al. Journal of Proteomics 2019;192:374-382. PubMed · Publisher

• The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. L. Mileshkin, C. Dunn, H. Cross, et al. Internal Medicine Journal 2019;49(8):1001-1006. PubMed · Publisher

• Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. G.L. Ceresoli, J.G. Aerts, R. Dziadziuszko, et al. The Lancet. Oncology 2019;20(12):1702-1709. PubMed · Publisher

• Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. S. Muruganandan, M. Azzopardi, D.B. Fitzgerald, et al. The Lancet. Respiratory Medicine 2018;6(9):671-680. Randomized trial PubMed · Publisher

• Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey. R. Morales-Soriano, N. Esteve-Pérez, J.J. Segura-Sampedro, et al. European Journal of Surgical Oncology 2018;44(2):228-236. PubMed · Publisher

• Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years. A. Scalabre, P. Philippe-Chomette, G. Passot, et al. Pediatric Blood & Cancer 2018;65(4). PubMed · Publisher

• Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial. S.A. Stewart, A.O. Clive, N.A. Maskell, et al. PloS One 2018;13(2):e0190257. Randomized trial PubMed · Publisher · Free full text

• Global trends in mortality from malignant mesothelioma: Analysis of WHO mortality database (1994-2013). O. Abdel-Rahman. The Clinical Respiratory Journal 2018;12(6):2090-2100. PubMed · Publisher

• Low-dose chest computed tomography screening of subjects exposed to asbestos. K. Kato, K. Gemba, K. Ashizawa, et al. European Journal of Radiology 2018;101:124-128. PubMed · Publisher

• Methylation-derived Neutrophil-to-Lymphocyte Ratio and Lung Cancer Risk in Heavy Smokers. L. Grieshober, S. Graw, M.J. Barnett, et al. Cancer Prevention Research 2018;11(11):727-734. Randomized trial PubMed · Publisher · Free full text

• Mortality in a cohort of asbestos-exposed workers undergoing health surveillance. F. Barbiero, T. Zanin, F.E. Pisa, et al. La Medicina del Lavoro 2018;109(2):83-86. PubMed · Publisher · Free full text

• Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study. M. Nowacki, M. Alyami, L. Villeneuve, et al. European Journal of Surgical Oncology 2018;44(7):991-996. PubMed · Publisher

• National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. S.A. Saddoughi, Z.M. Abdelsattar, S.H. Blackmon. The Annals of Thoracic Surgery 2018;105(2):432-437. PubMed · Publisher

• New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. F. Galateau Salle, N. Le Stang, A.G. Nicholson, et al. Journal of Thoracic Oncology 2018;13(8):1189-1203. PubMed · Publisher · Free full text

• NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. V. Gregorc, R.M. Gaafar, A. Favaretto, et al. The Lancet. Oncology 2018;19(6):799-811. Randomized trial PubMed · Publisher

• Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. L.E. Rosen, T. Karrison, V. Ananthanarayanan, et al. Modern Pathology 2018;31(4):598-606. PubMed · Publisher

• Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. G. Pelosi, M. Papotti, L. Righi, et al. Journal of Thoracic Oncology 2018;13(11):1750-1761. PubMed · Publisher

• Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. H.J. Gray, K. Bell-McGuinn, G.F. Fleming, et al. Gynecologic Oncology 2018;148(3):507-514. PubMed · Publisher

• Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions. M.E. Froudarakis, J. Plojoux, E. Kaspi, et al. The Clinical Respiratory Journal 2018;12(3):1011-1016. PubMed · Publisher

• Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients. M. de Mol, S. Visser, J.G.J.V. Aerts, et al. BMC Cancer 2018;18(1):1173. PubMed · Publisher · Free full text

• The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study. S. Takamori, G. Toyokawa, M. Shimokawa, et al. Annals of Surgical Oncology 2018;25(6):1555-1563. PubMed · Publisher

• The diagnostic role of BAP1 in serous effusions. B. Davidson, M. Tötsch, J. Wohlschlaeger, et al. Human Pathology 2018;79:122-126. PubMed · Publisher

• Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial. D. de Fonseka, A. Morley, L. Stadon, et al. Trials 2018;19(1):467. Randomized trial PubMed · Publisher · Free full text

• A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. S.A. Laurie, D. Hao, N.B. Leighl, et al. Lung Cancer 2017;104:65-69. PubMed · Publisher

• Association between lung cancer somatic mutations and occupational exposure in never-smokers. C. Paris, P. Do, B. Mastroianni, et al. The European Respiratory Journal 2017;50(4). PubMed · Publisher

• Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. M. Mencoboni, R.A. Filiberti, P. Taveggia, et al. Oncology Research and Treatment 2017;40(6):364-369. Review PubMed · Publisher

• Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. E.W. Alley, J. Lopez, A. Santoro, et al. The Lancet. Oncology 2017;18(5):623-630. PubMed · Publisher

• Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). D. Goéré, G. Passot, M. Gelli, et al. International Journal of Hyperthermia 2017;33(5):520-527. PubMed · Publisher

• Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method. M. Chen, E. Helm, N. Joshi, et al. International Journal of Computer Assisted Radiology and Surgery 2017;12(4):529-538. PubMed · Publisher · Free full text

• Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial. M. Zhan, H. Zheng, T. Xu, et al. Lung Cancer 2017;110:1-6. Randomized trial PubMed · Publisher

• Exhaled breath to screen for malignant pleural mesothelioma: a validation study. K. Lamote, M. Vynck, O. Thas, et al. The European Respiratory Journal 2017;50(6). PubMed · Publisher

• Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. J. Behr, P. Neuser, A. Prasse, et al. BMC Pulmonary Medicine 2017;17(1):122. Randomized trial PubMed · Publisher · Free full text

• External validation of prognostic indices for overall survival of malignant pleural mesothelioma. Y. Kataoka, Y. Yamamoto, T. Otsuki, et al. Lung Cancer 2017;113:88-92. PubMed · Publisher

• Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer. D. Owen, B.S. Sheffield, D. Ionescu, et al. Human Pathology 2017;60:82-85. PubMed · Publisher

• Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. M. Alyami, J. Gagniere, O. Sgarbura, et al. European Journal of Surgical Oncology 2017;43(11):2178-2183. PubMed · Publisher

• Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. E. Beddowes, J. Spicer, P.Y. Chan, et al. Journal of Clinical Oncology 2017;35(16):1778-1785. PubMed · Publisher · Free full text

• Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. S. Aspeslagh, K. Shailubhai, R. Bahleda, et al. Cancer Chemotherapy and Pharmacology 2017;79(6):1257-1265. PubMed · Publisher

• Reproducibility for histologic parameters in peritoneal mesothelioma. D.J. Hartman, A. Borczuk, S. Dacic, et al. Human Pathology 2017;67:54-59. PubMed · Publisher

• Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. N. van Zandwijk, N. Pavlakis, S.C. Kao, et al. The Lancet. Oncology 2017;18(10):1386-1396. PubMed · Publisher

• Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors. H.J. Meyer, L. Leifels, A.G. Bach, et al. Medicine 2017;96(36):e7985. PubMed · Publisher · Free full text

• The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy. S. Tsim, D.B. Stobo, L. Alexander, et al. Lung Cancer 2017;103:38-43. PubMed · Publisher · Free full text

• The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. L.M. Dowman, C.F. McDonald, C.J. Hill, et al. Thorax 2017;72(7):610-619. Randomized trial PubMed · Publisher

• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. M. Maio, A. Scherpereel, L. Calabrò, et al. The Lancet. Oncology 2017;18(9):1261-1273. Randomized trial PubMed · Publisher

• A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. V.W. Rusch, R. Gill, A. Mitchell, et al. The Annals of Thoracic Surgery 2016;102(4):1059-66. PubMed · Publisher · Free full text

• Asbestosis and other pulmonary fibrosis in asbestos-exposed workers: high-resolution CT features with pathological correlations. H. Arakawa, T. Kishimoto, K. Ashizawa, et al. European Radiology 2016;26(5):1485-92. PubMed · Publisher

• CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. M. Betti, A. Aspesi, A. Biasi, et al. Cancer Letters 2016;378(2):120-30. PubMed · Publisher

• Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS). K. Lamote, M. Vynck, J. Van Cleemput, et al. Journal of Breath Research 2016;10(4):046001. PubMed · Publisher

• Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. S. Tsim, C. Kelly, L. Alexander, et al. BMJ Open 2016;6(11):e013324. PubMed · Publisher · Free full text

• Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. V. Kepenekian, D. Elias, G. Passot, et al. European Journal of Cancer 2016;65:69-79. PubMed · Publisher

• Imaging of mesothelioma of tunica vaginalis testis. M. Bertolotto, I. Boulay-Coletta, R. Butini, et al. European Radiology 2016;26(3):631-8. PubMed · Publisher

• Management of malignant pleural mesothelioma - part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. T. Klikovits, M.A. Hoda, Y. Dong, et al. Wiener Klinische Wochenschrift 2016;128(17-18):627-34. PubMed · Publisher · Free full text

• MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. B. Davidson, H.T. Stavnes, E. Hellesylt, et al. Human Pathology 2016;47(1):104-8. PubMed · Publisher

• North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study. R.R. Gill, D.P. Naidich, A. Mitchell, et al. Journal of Thoracic Oncology 2016;11(8):1335-1344. PubMed · Publisher · Free full text

• Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. S.O. Dolly, A.J. Wagner, J.C. Bendell, et al. Clinical Cancer Research 2016;22(12):2874-84. PubMed · Publisher · Free full text

• Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. A.O. Clive, H. Taylor, L. Dobson, et al. The Lancet. Oncology 2016;17(8):1094-1104. Randomized trial PubMed · Publisher · Free full text

• Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. N. Bayman, D. Ardron, L. Ashcroft, et al. BMJ Open 2016;6(1):e010589. Randomized trial PubMed · Publisher · Free full text

• Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. M. Azzopardi, R. Thomas, S. Muruganandan, et al. BMJ Open 2016;6(7):e011480. Randomized trial PubMed · Publisher · Free full text

• Quantifying the mediating effects of smoking and occupational exposures in the relation between education and lung cancer: the ICARE study. G. Menvielle, J.E. Franck, L. Radoï, et al. European Journal of Epidemiology 2016;31(12):1213-1221. PubMed · Publisher

• Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). S. Hasegawa, M. Okada, F. Tanaka, et al. International Journal of Clinical Oncology 2016;21(3):523-30. PubMed · Publisher · Free full text

• Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study. C.K. Lin, Y.Y. Chang, J.D. Wang, et al. BioMed Research International 2015;2015:678598. PubMed · Publisher · Free full text

• Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations: A Multicenter Observational Study. R. Thomas, F. Piccolo, D. Miller, et al. Chest 2015;148(3):746-751. PubMed · Publisher

• Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. N. MacLeod, A. Chalmers, N. O'Rourke, et al. Journal of Thoracic Oncology 2015;10(6):944-50. PubMed · Publisher

• Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. B. Ghanim, T. Klikovits, M.A. Hoda, et al. British Journal of Cancer 2015;112(5):783-92. PubMed · Publisher · Free full text

• Lung cancer risk among bricklayers in a pooled analysis of case-control studies. D. Consonni, S. De Matteis, A.C. Pesatori, et al. International Journal of Cancer 2015;136(2):360-71. PubMed · Publisher · Free full text

• Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). C. Raynaud, L. Greillier, J. Mazieres, et al. BMC Cancer 2015;15:857. PubMed · Publisher · Free full text

• MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. G. Pasello, L. Urso, M. Mencoboni, et al. Oncotarget 2015;6(39):42053-66. PubMed · Publisher · Free full text

• Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. R.A. Stahel, O. Riesterer, A. Xyrafas, et al. The Lancet. Oncology 2015;16(16):1651-8. Randomized trial PubMed · Publisher

• Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. T.R. van Oudheusden, V.E. Lemmens, H.J. Braam, et al. Surgery 2015;157(6):1023-7. PubMed · Publisher

• Postoperative morbidity and mortality after pneumonectomy: a 30-year experience of 2064 consecutive patients. C. Pricopi, P. Mordant, C. Rivera, et al. Interactive Cardiovascular and Thoracic Surgery 2015;20(3):316-21. PubMed · Publisher

• Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. E.T.H. Fysh, S. Bielsa, C.A. Budgeon, et al. Chest 2015;147(6):1629-1634. PubMed · Publisher

• Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. A. Rusch, G. Ziltener, K. Nackaerts, et al. Lung Cancer 2015;87(1):77-9. PubMed · Publisher

• Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis. G. Leuzzi, F. Rea, L. Spaggiari, et al. The Annals of Thoracic Surgery 2015;100(3):890-7. PubMed · Publisher

• Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS). D.B. Richardson, E. Cardis, R.D. Daniels, et al. BMJ 2015;351:h5359. PubMed · Publisher · Free full text

• Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers. A.C. Bibby, A.O. Clive, G.C. Slade, et al. Chest 2015;148(1):235-241. PubMed · Publisher

• The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. D.T. Arnold, C.E. Hooper, A. Morley, et al. British Journal of Cancer 2015;112(7):1183-9. PubMed · Publisher · Free full text

• The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. C.E. Hooper, I.D. Lyburn, J. Searle, et al. British Journal of Cancer 2015;112(7):1175-82. PubMed · Publisher · Free full text

• A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial. S. Gunatilake, F.J. Brims, C. Fogg, et al. Trials 2014;15:367. Randomized trial PubMed · Publisher · Free full text

• A six-year review of more than 13,000 patient-specific IMRT QA results from 13 different treatment sites. K.B. Pulliam, D. Followill, L. Court, et al. Journal of Applied Clinical Medical Physics 2014;15(5):4935. Review PubMed · Publisher · Free full text

• Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. B. Ghanim, M.A. Hoda, T. Klikovits, et al. British Journal of Cancer 2014;110(4):984-90. PubMed · Publisher · Free full text

• Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. J. Creaney, I.M. Dick, T.M. Meniawy, et al. Thorax 2014;69(10):895-902. PubMed · Publisher · Free full text

• Continued spirometry changes after cessation of exposure in asbestos-cement workers. B. Swiątkowska, W. Sobala, Z. Szubert, et al. Journal of Occupational and Environmental Medicine 2014;56(4):403-8. PubMed · Publisher

• Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. T. Powrózek, D.M. Kowalski, P. Krawczyk, et al. Clinical Lung Cancer 2014;15(6):455-65. PubMed · Publisher

• Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. P. Bovolato, C. Casadio, A. Billè, et al. Journal of Thoracic Oncology 2014;9(3):390-6. PubMed · Publisher

• Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. L. Spaggiari, G. Marulli, P. Bovolato, et al. The Annals of Thoracic Surgery 2014;97(6):1859-65. PubMed · Publisher

• Lymph node involvement and metastatic lymph node ratio influence the survival of malignant pleural mesothelioma: a French multicenter retrospective study. I. Hysi, F. Le Pimpec-Barthes, M. Alifano, et al. Oncology Reports 2014;31(1):415-21. PubMed · Publisher

• Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. R. Hassan, H.L. Kindler, T. Jahan, et al. Clinical Cancer Research 2014;20(23):5927-36. PubMed · Publisher · Free full text

• Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. G.L. Ceresoli, F. Grosso, P.A. Zucali, et al. British Journal of Cancer 2014;111(2):220-6. PubMed · Publisher · Free full text

• Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study. H. Mutlu, S. Gündüz, H. Karaca, et al. Medical Oncology 2014;31(8):74. PubMed · Publisher

• Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. M. Bayram, I. Dongel, A. Akbaş, et al. Lung 2014;192(1):197-203. PubMed · Publisher

• Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis. H. Suzuki, K. Asami, T. Hirashima, et al. Lung 2014;192(1):191-5. PubMed · Publisher

• The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. M. Dogan, G. Utkan, C. Hocazade, et al. Medical Oncology 2014;31(10):232. PubMed · Publisher

• Well-differentiated papillary mesothelioma with invasive foci. A. Churg, T. Allen, A.C. Borczuk, et al. The American Journal of Surgical Pathology 2014;38(7):990-8. PubMed · Publisher

• A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication aimed at macroscopic complete resection for malignant pleural mesothelioma. M. Shimokawa, S. Hasegawa, K. Fukuoka, et al. Japanese Journal of Clinical Oncology 2013;43(5):575-8. PubMed · Publisher

• A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. A.K. Nowak, C. Brown, M.J. Millward, et al. Lung Cancer 2013;81(3):422-427. PubMed · Publisher

• Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. G. Utkan, Y. Ürün, A.K. Cangir, et al. Asian Pacific Journal of Cancer Prevention 2013;14(1):249-53. PubMed

• Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study. B. Courbiere, C. Decanter, S. Bringer-Deutsch, et al. Human Reproduction 2013;28(9):2381-8. PubMed · Publisher

• Opioids in pain management of mesothelioma and lung cancer patients. E.K. Salminen, M. Silvoniemi, K. Syrjänen, et al. Acta Oncologica 2013;52(1):30-7. PubMed · Publisher

• Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. S. Papa, S. Popat, R. Shah, et al. Journal of Thoracic Oncology 2013;8(6):783-7. PubMed · Publisher

• Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). M.E. O'Brien, R.M. Gaafar, S. Popat, et al. European Journal of Cancer 2013;49(13):2815-22. PubMed · Publisher

• Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. G.L. Ceresoli, P.A. Zucali, M. Mencoboni, et al. British Journal of Cancer 2013;109(3):552-8. PubMed · Publisher · Free full text

• Pleural plaques and the risk of pleural mesothelioma. J.C. Pairon, F. Laurent, M. Rinaldo, et al. Journal of the National Cancer Institute 2013;105(4):293-301. PubMed · Publisher

• Pleurodesis outcome in malignant pleural mesothelioma. E.T. Fysh, S.K. Tan, C.A. Read, et al. Thorax 2013;68(6):594-6. PubMed · Publisher

• Risk of lung cancer associated with occupational exposure to mineral wools: updating knowledge from a french population-based case-control study, the ICARE study. F. Guida, S. Paget-Bailly, F. Lamkarkach, et al. Journal of Occupational and Environmental Medicine 2013;55(7):786-95. PubMed · Publisher

• Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. N. Blais, D.R. Camidge, D.J. Jonker, et al. Investigational New Drugs 2013;31(6):1487-98. PubMed · Publisher · Free full text

• Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. D.R. Camidge, N. Blais, D.J. Jonker, et al. Cancer Chemotherapy and Pharmacology 2013;71(2):307-19. PubMed · Publisher

• Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. W.A. Buikhuisen, J.A. Burgers, A.D. Vincent, et al. The Lancet. Oncology 2013;14(6):543-51. Randomized trial PubMed · Publisher

• The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. A. Paintal, K. Raparia, M.F. Zakowski, et al. Cancer Cytopathology 2013;121(12):703-7. PubMed · Publisher

• The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. D.J. Pinato, F.A. Mauri, T. Lloyd, et al. British Journal of Cancer 2013;108(3):621-8. PubMed · Publisher · Free full text

• Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. H.R. Alexander, D.L. Bartlett, J.F. Pingpank, et al. Surgery 2013;153(6):779-86. PubMed · Publisher · Free full text

• A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. D.T. Le, D.G. Brockstedt, R. Nir-Paz, et al. Clinical Cancer Research 2012;18(3):858-68. PubMed · Publisher · Free full text

• A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. J.E. Dowell, F.R. Dunphy, R.N. Taub, et al. Lung Cancer 2012;77(3):567-71. PubMed · Publisher

• Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. N.P. Campbell, R. Kunnavakkam, N. Leighl, et al. Lung Cancer 2012;78(1):76-80. PubMed · Publisher · Free full text

• CT scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. A.K. Greenberg, F. Lu, J.D. Goldberg, et al. PloS One 2012;7(7):e39403. PubMed · Publisher · Free full text

• Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. R.M. Ostroff, M.R. Mehan, A. Stewart, et al. PloS One 2012;7(10):e46091. PubMed · Publisher · Free full text

• Importance of gender in diffuse malignant peritoneal mesothelioma. C. Cao, T.D. Yan, M. Deraco, et al. Annals of Oncology 2012;23(6):1494-8. PubMed · Publisher

• Initial analysis of the international association for the study of lung cancer mesothelioma database. V.W. Rusch, D. Giroux, C. Kennedy, et al. Journal of Thoracic Oncology 2012;7(11):1631-9. PubMed · Publisher

• Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. E.T. Elkiran, M.A. Kaplan, A. Sevinc, et al. Medical Oncology 2012;29(5):3147-54. PubMed · Publisher

• Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. B. Saraiya, R. Chugh, V. Karantza, et al. Investigational New Drugs 2012;30(1):258-65. PubMed · Publisher · Free full text

• Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma. D.A. Fennell, C. McDowell, S. Busacca, et al. Journal of Thoracic Oncology 2012;7(9):1466-70. PubMed · Publisher

• Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. G. Levallet, M. Vaisse-Lesteven, N. Le Stang, et al. Journal of Thoracic Oncology 2012;7(3):599-606. PubMed · Publisher

• Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma. V. Pinelli, S. Laroumagne, L. Sakr, et al. Journal of Thoracic Oncology 2012;7(3):595-8. PubMed · Publisher

• Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients. R.S. Finn, F.J.H. Brims, A. Gandhi, et al. Chest 2012;142(5):1267-1273. PubMed · Publisher

• Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. B. Ghanim, M.A. Hoda, M.P. Winter, et al. Annals of Surgery 2012;256(2):357-62. PubMed · Publisher

• Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. A. Bearz, R. Talamini, G. Rossoni, et al. BMC Research Notes 2012;5:482. PubMed · Publisher · Free full text

• Re-evaluation of histological findings of nonparasitic splenic cysts. P. Vajda, L. Kereskai, P. Czauderna, et al. European Journal of Gastroenterology & Hepatology 2012;24(3):316-9. PubMed · Publisher

• Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. K. Kuribayashi, S. Voss, S. Nishiuma, et al. Lung Cancer 2012;75(3):353-9. PubMed · Publisher

• Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. P.A. Zucali, M. Simonelli, G. Michetti, et al. Lung Cancer 2012;75(3):360-7. PubMed · Publisher

• The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. K. Hollevoet, K. Nackaerts, O. Thas, et al. Chest 2012;141(2):477-484. PubMed · Publisher

• Ureteral stenting in cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy as a routine procedure: evidence and necessity. F. Coccolini, M. Lotti, R. Manfredi, et al. Urologia Internationalis 2012;89(3):307-10. PubMed · Publisher

• Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). T. Jahan, L. Gu, R. Kratzke, et al. Lung Cancer 2012;76(3):393-6. PubMed · Publisher · Free full text

• Adjuvant radiotherapy after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. S. Tonoli, P. Vitali, V. Scotti, et al. Radiotherapy and Oncology 2011;101(2):311-5. PubMed · Publisher

• Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. S.A. Laurie, A. Gupta, Q. Chu, et al. Journal of Thoracic Oncology 2011;6(11):1950-4. PubMed · Publisher

• Comparison of exposure assessment methods for occupational carcinogens in a multi-centre lung cancer case-control study. S. Peters, R. Vermeulen, A. Cassidy, et al. Occupational and Environmental Medicine 2011;68(2):148-53. PubMed · Publisher

• Do asbestos-related pleural plaques on HRCT scans cause restrictive impairment in the absence of pulmonary fibrosis?. B. Clin, C. Paris, J. Ameille, et al. Thorax 2011;66(11):985-91. PubMed · Publisher

• Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. T. Treasure, L. Lang-Lazdunski, D. Waller, et al. The Lancet. Oncology 2011;12(8):763-72. Randomized trial PubMed · Publisher · Free full text

• Helical tomotherapy for resected malignant pleural mesothelioma: dosimetric evaluation and toxicity. P. Giraud, A. Sylvestre, S. Zefkili, et al. Radiotherapy and Oncology 2011;101(2):303-6. PubMed · Publisher

• Identifying patients with suspected lung cancer in primary care: derivation and validation of an algorithm. J. Hippisley-Cox, C. Coupland. The British Journal of General Practice 2011;61(592):e715-23. PubMed · Publisher · Free full text

• Investigation of occupational and environmental causes of respiratory cancers (ICARE): a multicenter, population-based case-control study in France. D. Luce, I. Stücker, ICARE Study Group. BMC Public Health 2011;11:928. PubMed · Publisher · Free full text

• Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. T.C. Chua, T.D. Yan, M. Deraco, et al. The British Journal of Surgery 2011;98(1):60-4. PubMed · Publisher

• Occupational exposure to dusts and risk of renal cell carcinoma. S. Karami, P. Boffetta, P.S. Stewart, et al. British Journal of Cancer 2011;104(11):1797-803. PubMed · Publisher · Free full text

• Prophylactic irradiation of intervention sites in malignant pleural mesothelioma. M.A. Froment, E. Fréchette, A. Dagnault. Radiotherapy and Oncology 2011;101(2):307-10. PubMed · Publisher

• Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. K. Hollevoet, K. Nackaerts, R. Gosselin, et al. Journal of Thoracic Oncology 2011;6(11):1930-7. PubMed · Publisher

• Tumor type influences the effectiveness of pleurodesis in malignant effusions. S. Bielsa, P. Hernández, F. Rodriguez-Panadero, et al. Lung 2011;189(2):151-5. PubMed · Publisher

  In plain English

  This retrospective study at two Spanish hospitals asked whether cancer type affects pleurodesis success. Pleurodesis seals the space around the lung to stop fluid returning. It covered 126 patients given doxycycline in Lleida and 447 given talc during thoracoscopy in Sevilla. Asbestos was not studied; mesothelioma was one cancer type. With talc, failure rates were 24% for mesothelioma and 15% for lung cancer, versus 7.5% for breast cancer and 9% for other cancers spread to the pleura (p = 0.012). With doxycycline, complete response rates were 31% for lung cancer, 54% for breast cancer and 74% for cancers spread from sites other than lung or breast (p = 0.001). Only one doxycycline patient had mesothelioma. After allowing for the amount of pleural tumor, breast cancer and cancers spread from sites other than lung or breast still did better with talc than mesothelioma. Lung cancer did not differ significantly from mesothelioma, and more pleural tumor was linked to more failures. The authors concluded that tumor type influences pleurodesis success but should not alone be used to deny the procedure. They noted possible bias from the retrospective design.

  We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

• A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. S. Dubey, P.A. Jänne, L. Krug, et al. Journal of Thoracic Oncology 2010;5(10):1655-61. PubMed · Publisher · Free full text

• Asbestos exposure and malignant lymphoma: a multicenter case-control study in Germany and Italy. A. Seidler, N. Becker, A. Nieters, et al. International Archives of Occupational and Environmental Health 2010;83(5):563-70. PubMed · Publisher

• Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. K. Hollevoet, K. Nackaerts, J. Thimpont, et al. American Journal of Respiratory and Critical Care Medicine 2010;181(6):620-5. PubMed · Publisher

• Malignant peritoneal mesothelioma: a multicenter study on 81 cases. V.P. Manzini, L. Recchia, M. Cafferata, et al. Annals of Oncology 2010;21(2):348-353. PubMed · Publisher

• Multicystic peritoneal mesothelioma: outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). D. Baratti, M. Vaira, S. Kusamura, et al. European Journal of Surgical Oncology 2010;36(11):1047-53. PubMed · Publisher

• Occupational exposure to polycyclic aromatic hydrocarbons and lung cancer risk: a multicenter study in Europe. A.C. Olsson, J. Fevotte, T. Fletcher, et al. Occupational and Environmental Medicine 2010;67(2):98-103. PubMed · Publisher

• Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. R. Hassan, S.J. Cohen, M. Phillips, et al. Clinical Cancer Research 2010;16(24):6132-8. PubMed · Publisher · Free full text

• Programmed health surveillance and detection of emerging diseases in occupational health: contribution of the French national occupational disease surveillance and prevention network (RNV3P). V. Bonneterre, L. Faisandier, D. Bicout, et al. Occupational and Environmental Medicine 2010;67(3):178-86. PubMed · Publisher

• Prospective study of asbestos-related diseases incidence cases in primary health care in an area of Barcelona province. M. Rosell-Murphy, R. Abós-Herràndiz, J. Tarrés, et al. BMC Public Health 2010;10:203. PubMed · Publisher · Free full text

• Second surgery for recurrence of malignant pleural mesothelioma after extrapleural pneumonectomy. L. Politi, G. Borzellino. The Annals of Thoracic Surgery 2010;89(1):207-10. PubMed · Publisher

• Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. P.E. Van Schil, P. Baas, R. Gaafar, et al. The European Respiratory Journal 2010;36(6):1362-9. PubMed · Publisher

2000s

• Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. A. Cassidy, J. Balsan, A. Vesin, et al. European Journal of Cancer 2009;45(17):3047-53. PubMed · Publisher
• Estimates of historical exposures by phase contrast and transmission electron microscopy in North Carolina USA asbestos textile plants. J.M. Dement, D. Myers, D. Loomis, et al. Occupational and Environmental Medicine 2009;66(9):574-83. PubMed · Publisher
• Lung cancer mortality and fibre exposures among North Carolina asbestos textile workers. D. Loomis, J.M. Dement, S.H. Wolf, et al. Occupational and Environmental Medicine 2009;66(8):535-42. PubMed · Publisher
• Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. M.L. De Bruin, J.A. Burgers, P. Baas, et al. Blood 2009;113(16):3679-81. PubMed · Publisher
• Mortality among British asbestos workers undergoing regular medical examinations (1971-2005). A.H. Harding, A. Darnton, J. Wegerdt, et al. Occupational and Environmental Medicine 2009;66(7):487-95. PubMed · Publisher
• Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. J.A. Rodríguez Portal, E. Rodríguez Becerra, D. Rodríguez Rodríguez, et al. Cancer Epidemiology, Biomarkers & Prevention 2009;18(2):646-50. PubMed · Publisher
• Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. M.F. Muers, R.J. Stephens, P. Fisher, et al. Lancet 2008;371(9625):1685-94. Randomized trial PubMed · Publisher · Free full text
• Development and validation of a lung cancer risk prediction model for African-Americans. C.J. Etzel, S. Kachroo, M. Liu, et al. Cancer Prevention Research 2008;1(4):255-65. PubMed · Publisher · Free full text
• Occupational exposures and risk of oesophageal cancer by histological type: a case-control study in eastern Spain. M. Santibañez, J. Vioque, J. Alguacil, et al. Occupational and Environmental Medicine 2008;65(11):774-81. PubMed · Publisher
• Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. K. Shiomi, Y. Hagiwara, K. Sonoue, et al. Clinical Cancer Research 2008;14(5):1431-7. PubMed · Publisher
• Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. G. Hillerdal, J.B. Sorensen, S. Sundström, et al. Journal of Thoracic Oncology 2008;3(11):1325-31. PubMed · Publisher
• Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. A. Marinaccio, A. Binazzi, G. Cauzillo, et al. European Journal of Cancer 2007;43(18):2722-8. PubMed · Publisher
• Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). G. Fasola, O. Belvedere, M. Aita, et al. The Oncologist 2007;12(10):1215-24. PubMed · Publisher
• Occupational exposure to asbestos and man-made vitreous fibres and risk of lung cancer: a multicentre case-control study in Europe. R. Carel, A.C. Olsson, D. Zaridze, et al. Occupational and Environmental Medicine 2007;64(8):502-8. PubMed · Publisher · Free full text
• Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. J.Y. Choi, M.L. Neuhouser, M. Barnett, et al. Cancer Epidemiology, Biomarkers & Prevention 2007;16(6):1115-20. Randomized trial PubMed · Publisher
• Spirometry, rapid FEV1 decline, and lung cancer among asbestos exposed heavy smokers. J.W. Chien, D.H. Au, M.J. Barnett, et al. COPD 2007;4(4):339-46. Randomized trial PubMed · Publisher
• Estimates of work-related cancers in workers exposed to carcinogens. F. Deschamps, M. Barouh, G. Deslee, et al. Occupational Medicine 2006;56(3):204-9. PubMed · Publisher
• Exposure to non-arsenic pesticides is associated with lymphoma among farmers in Spain. E. van Balen, R. Font, N. Cavallé, et al. Occupational and Environmental Medicine 2006;63(10):663-8. PubMed · Publisher · Free full text
• Occupational exposure and laryngeal and hypopharyngeal cancer risk in central and eastern Europe. O. Shangina, P. Brennan, N. Szeszenia-Dabrowska, et al. American Journal of Epidemiology 2006;164(4):367-75. PubMed · Publisher
• The French National Mesothelioma Surveillance Program. M. Goldberg, E. Imbernon, P. Rolland, et al. Occupational and Environmental Medicine 2006;63(6):390-5. PubMed · Publisher · Free full text
• A cancer incidence and mortality study of Dow Chemical Canada Inc. manufacturing sites. C. Burns, K. Harrison, B. Jammer, et al. Occupational Medicine 2005;55(8):618-24. PubMed · Publisher
• A comparison of fibre counting across three European national proficiency testing schemes. A.D. Jones, M.C. Arroyo, R. Grosjean, et al. The Annals of Occupational Hygiene 2005;49(4):309-24. PubMed · Publisher
• Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma. L. Portalone, A. Antilli, F. Nunziati, et al. Tumori 2005;91(1):15-8. PubMed · Publisher
• Evidence for excess colorectal cancer incidence among asbestos-exposed men in the Beta-Carotene and Retinol Efficacy Trial. O.A. Aliyu, M.R. Cullen, M.J. Barnett, et al. American Journal of Epidemiology 2005;162(9):868-78. PubMed · Publisher
• Asbestos exposure and radiological abnormalities among maintenance and custodian workers in buildings with friable asbestos-containing materials. M. Matrat, J.C. Pairon, A.G. Paolillo, et al. International Archives of Occupational and Environmental Health 2004;77(5):307-12. PubMed · Publisher
• Asbestos exposure as a risk factor for retroperitoneal fibrosis. T. Uibu, P. Oksa, A. Auvinen, et al. Lancet 2004;363(9419):1422-6. PubMed · Publisher
• Asbestos-related pleural diseases: dimensional criteria are not appropriate to differentiate diffuse pleural thickening from pleural plaques. J. Ameille, M. Matrat, C. Paris, et al. American Journal of Industrial Medicine 2004;45(3):289-96. PubMed · Publisher
• Occupations and exposures in the work environment as determinants for rheumatoid arthritis. A.R. Olsson, T. Skogh, O. Axelson, et al. Occupational and Environmental Medicine 2004;61(3):233-8. PubMed · Publisher · Free full text
• Cancer mortality among European asphalt workers: an international epidemiological study. II. Exposure to bitumen fume and other agents. P. Boffetta, I. Burstyn, T. Partanen, et al. American Journal of Industrial Medicine 2003;43(1):28-39. PubMed · Publisher
• Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. J. Alguacil, M. Porta, T. Kauppinen, et al. International Journal of Cancer 2003;107(4):635-41. PubMed · Publisher
• A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. A.K. Nowak, M.J. Byrne, R. Williamson, et al. British Journal of Cancer 2002;87(5):491-6. PubMed · Publisher · Free full text
• Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. J.M. van Haarst, P. Baas, C.H. Manegold, et al. British Journal of Cancer 2002;86(3):342-5. PubMed · Publisher · Free full text
• Phase II trial of ZD0473 as second-line therapy in mesothelioma. G. Giaccone, M.E. O'Brien, M.J. Byrne, et al. European Journal of Cancer 2002;38 Suppl 8:S19-24. PubMed · Publisher
• High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. M.P. Kosty, J.E. Herndon, N.J. Vogelzang, et al. Lung Cancer 2001;34(2):289-95. PubMed · Publisher
• Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. C. Magnani, A. Agudo, C.A. González, et al. British Journal of Cancer 2000;83(1):104-11. PubMed · Publisher · Free full text
• Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. B. Pesch, J. Haerting, U. Ranft, et al. International Journal of Epidemiology 2000;29(6):1014-24. PubMed · Publisher
• The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. O. Genc, M. Petrou, G. Ladas, et al. European Journal of Cardio-thoracic Surgery 2000;18(2):143-6. PubMed · Publisher

1990s

• Case-control study of mesothelioma in South Africa. D. Rees, J.E. Myers, K. Goodman, et al. American Journal of Industrial Medicine 1999;35(3):213-22. PubMed · Publisher

• Dose-response relationship between amphibole fiber lung burden and mesothelioma. K. Rödelsperger, H.J. Woitowitz, B. Brückel, et al. Cancer Detection and Prevention 1999;23(3):183-93. PubMed · Publisher

• p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. J. Schneider, P. Presek, A. Braun, et al. British Journal of Cancer 1999;80(12):1987-94. PubMed · Publisher · Free full text

• Serum levels of pantropic p53 protein and EGF-receptor, and detection of anti-p53 antibodies in former uranium miners (SDAG Wismut). J. Schneider, P. Presek, A. Braun, et al. American Journal of Industrial Medicine 1999;36(6):602-9. PubMed · Publisher

• Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases. M.N. Koss, M. Fleming, R.M. Przygodzki, et al. Annals of Diagnostic Pathology 1998;2(2):93-102. Case report PubMed · Publisher

• Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. S. Bretti, A. Berruti, L. Dogliotti, et al. Tumori 1998;84(5):558-61. PubMed · Publisher

• Malignant intraperitoneal neoplasms of childhood. C.J. Chung, V. Bui, L.A. Fordham, et al. Pediatric Radiology 1998;28(5):317-21. PubMed · Publisher

• Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. D.W. Henderson, K.B. Shilkin, D. Whitaker. American Journal of Clinical Pathology 1998;110(3):397-404. Review PubMed · Publisher

• Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. G.S. Omenn, G.E. Goodman, M.D. Thornquist, et al. The New England Journal of Medicine 1996;334(18):1150-5. Randomized trial PubMed · Publisher

• Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. J. van Meerbeeck, C. Debruyne, N. van Zandwijk, et al. British Journal of Cancer 1996;74(6):961-3. PubMed · Publisher · Free full text

• Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. G.S. Omenn, G.E. Goodman, M.D. Thornquist, et al. Journal of the National Cancer Institute 1996;88(21):1550-9. Randomized trial PubMed · Publisher

• Insulation, asbestos, smoking habits, and lung cancer cell types. J.E. Muscat, S.D. Stellman, E.L. Wynder. American Journal of Industrial Medicine 1995;27(2):257-69. PubMed · Publisher

  In plain English

  This hospital-based case-control study compared 2,871 men with lung cancer and 5,240 male hospital controls interviewed 1981 to 1991. Exposure measures were jobs likely to involve asbestos (mostly construction trades and mechanics), self-reported asbestos dust at work, and, from 1986, self-reported building insulation exposure. 22% of cases and 18% of controls held asbestos-related jobs. The odds ratio (OR) was 1.0 (95% CI 0.9 to 1.3) for current smokers and 1.3 (1.1 to 1.6) for ex-smokers. Self-reported asbestos dust exposure was linked to higher odds of lung cancer (all cell types combined): ORs 1.5 (1.1 to 2.1) and 2.5 (1.5 to 4.1) for current smokers in the earlier and later periods, and 1.9 (1.3 to 2.8) and 2.2 (1.4 to 3.5) for ex-smokers. Current smokers showed no significant trend with years exposed. For building insulation, ORs were 2.2 (1.2 to 4.3) in current smokers and 1.8 (0.9 to 3.6) in ex-smokers. Never smokers' OR for self-reported exposure, based on eight cases, was 2.0 (0.9 to 4.3), not statistically significant. The authors said recall bias and misclassification need consideration.

  We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

• International renal-cell cancer study. IV. Occupation. J.S. Mandel, J.K. McLaughlin, B. Schlehofer, et al. International Journal of Cancer 1995;61(5):601-5. PubMed · Publisher

• Occupational exposures to fibers and quartz at 19 crushed stone mining and milling operations. G.J. Kullman, A.L. Greife, J. Costello, et al. American Journal of Industrial Medicine 1995;27(5):641-60. PubMed · Publisher

• The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. G.S. Omenn, G. Goodman, M. Thornquist, et al. Cancer Research 1994;54(7 Suppl):2038s-2043s. Randomized trial PubMed

• Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. N.J. Vogelzang, L.B. Weissman, J.E. Herndon, et al. Journal of Clinical Oncology 1994;12(7):1436-42. PubMed · Publisher

• A mortality study among mild steel and stainless steel welders. J.J. Moulin, P. Wild, J.M. Haguenoer, et al. British Journal of Industrial Medicine 1993;50(3):234-43. PubMed · Publisher · Free full text

• Lung cancer and occupation: results of a multicentre case-control study. A. Morabia, S. Markowitz, K. Garibaldi, et al. British Journal of Industrial Medicine 1992;49(10):721-7. PubMed · Publisher · Free full text

• A historical prospective study of European stainless steel, mild steel, and shipyard welders. L. Simonato, A.C. Fletcher, A. Andersen, et al. British Journal of Industrial Medicine 1991;48(3):145-54. PubMed · Publisher · Free full text

• Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. V.W. Rusch, R. Figlin, D. Godwin, et al. Journal of Clinical Oncology 1991;9(2):313-9. PubMed · Publisher

• Participation and adherence among older men and women recruited to the Beta-Carotene and Retinol Efficacy trial (CARET). M.D. Thornquist, D.L. Patrick, G.S. Omenn. The Gerontologist 1991;31(5):593-7. PubMed · Publisher

1980s

• Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. P. Ruffie, R. Feld, S. Minkin, et al. Journal of Clinical Oncology 1989;7(8):1157-68. PubMed · Publisher

Browse every journal in the library or other types of article.